| Literature DB >> 28823120 |
Kondreddy Eswar Reddy1, Jin Young Jeong1, Yookyung Lee1, Hyun-Jeong Lee1, Min Seok Kim1, Dong-Wook Kim1, Hyun Jung Jung1, Changyong Choe2, Young Kyoon Oh1, Sung Dae Lee1.
Abstract
OBJECTIVE: The Fusarium mycotoxins of deoxynivalenol (DON) and zerolenone (ZEN) cause health hazards for both humans and farm animals. Therefore, the main intention of this study was to reveal DON and ZEN effects on the mRNA expression of pro-inflammatory cytokines and other immune related genes in the liver of piglets.Entities:
Keywords: Deoxynivalenol; Gene Expression; Immune System; Liver; Pig; Zerolenone
Year: 2017 PMID: 28823120 PMCID: PMC5838333 DOI: 10.5713/ajas.17.0466
Source DB: PubMed Journal: Asian-Australas J Anim Sci ISSN: 1011-2367 Impact factor: 2.509
Figure 1Expression counts of differentially expressed genes (DEGs) in control, deoxynivalenol (DON), and zerolenone (ZEN) treatment groups. The y-axis represents upregulation and downregulation of DEGs between control livers and mycotoxin-treated livers. The x-axis represents the total number of transcripts (DEGs for each pairwise comparison were considered at fold change [FC]>2 and p≤0.05).
Top biological process GO terms associated with the DEGs identified by comparing the DON and ZEN mycotoxin treatment groups with the control group
| Name | GOID | Term | Count | Genes | p-value |
|---|---|---|---|---|---|
| biological_process | GO:0002376 | Immune system process | 8 | 0.003 | |
| biological_process | GO:1901575 | Organic substance catabolic process | 7 | 0.005 | |
| biological_process | GO:0044248 | Cellular catabolic process | 7 | 0.005 | |
| biological_process | GO:0044281 | Small molecule metabolic process | 7 | 0.011 | |
| biological_process | GO:0019752 | Carboxylic acid metabolic process | 5 | 0.012 | |
| biological_process | GO:0009056 | Catabolic process | 7 | 0.013 | |
| biological_process | GO:0050896 | Response to stimulus | 17 | 0.013 | |
| biological_process | GO:0023051 | Regulation of signaling | 7 | 0.049 | |
| biological_process | GO:0043436 | Oxoacid metabolic process | 5 | 0.015 | |
| biological_process | GO:0006082 | Organic acid metabolic process | 5 | 0.016 | |
| biological_process | GO:1901605 | Alpha-amino acid metabolic process | 3 | 0.023 | |
| biological_process | GO:1901565 | Organonitrogen compound catabolic process | 3 | 0.024 | |
| biological_process | GO:0042104 | Positive regulation of activated T cell proliferation | 2 | 0.025 | |
| biological_process | GO:0045321 | Leukocyte activation | 4 | 0.026 | |
| biological_process | GO:0043567 | Regulation of insulin-like growth factor receptor signaling pathway | 2 | 0.028 | |
| biological_process | GO:0001775 | Cell activation | 4 | 0.041 | |
| biological_process | GO:0006520 | Cellular amino acid metabolic process | 3 | 0.046 |
GO, gene ontology; DEGs, differentially expressed genes; DON, deoxynivalenol; ZEN, zerolenone.
Gene ontology ID of the biological process.
Name of the biological term.
Number of significant genes which are involved in biological terms.
Name of the genes which are involved in the particular biological term.
Upregulated genes in the livers of piglets exposed to both deoxynivalenol (DON) (8 mg/kg) and zerolenone (ZEN) (0.8 mg/kg) dietary treatments
| Gene symbol | Gene description | Log2 FC | p-value | Biological process |
|---|---|---|---|---|
| Claudin 4 | 2.02 | 0.044 | Regulation of immune system process, acute-phase response | |
| Cytochrome P450, family 26, subfamily A, polypeptide 1 | 2.13 | 0.012 | Transport and catabolism, Retinol metabolism | |
| Insulin-like growth factor binding protein 2 | 2.75 | 0.028 | Growth regulation, response to insulin | |
| Orosomucoid 1 | 2.25 | 0.028 | Regulation of immune system process | |
| Fatty acidd hydroxylase domain containing 2 | 2.07 | 0.028 | Fatty acid biosynthetic process | |
| Sphingomyelin phosphodiesterase 3 | 2.21 | 0.033 | Hematopoietic progenitor cell differentiation | |
| Ornithine decarboxylase antizyme 3 | 3.46 | 0.017 | Polyamine metabolic process | |
| secretin | 2.49 | 0.037 | Hormone activity | |
| Ubiquitin D | 3.59 | 0.028 | Positive regulation of apoptotic process | |
| Carbonic anhydrase 2 | 2.10 | 0.048 | Morphogenesis of an epithelium | |
| Growth arrest specific | 2.33 | 0.047 | Regulation of apoptotic process | |
| Glutamic-pyruvic transaminase 2 | 5.90 | 0.002 | 2-oxoglutarate metabolic process | |
| Phosphatidylcholine transfer protein | 2.18 | 0.001 | Intracellular vesicular traffic | |
| Interleukin 10 receptor, beta | −2.10 | 0.031 | Cytokine-cytokine receptor interaction | |
| Insulin like growth factor 1 | −3.90 | 0.033 | Positive regulation of cell proliferation, activation of MAPK activity | |
| Ornithine aminotransferase | −2.02 | 0.047 | Arginine catabolic process to proline | |
| Nocturnin | −2.41 | 0.043 | Deadenylation-dependent decapping of nuclear-transcribed mRNA | |
| Nicotinamide N-methyl transferase | −4.09 | 0.032 | Promotes epigenetic remodeling in cancer | |
| Lipase G, endothelial type | −2.27 | 0.043 | Positive regulation of high-density lipoprotein particle clearance | |
| Salt inducible kinase 1 | −2.24 | 0.011 | Glucagon signaling pathway | |
| Thyrotropin releasing hormone degrading enzyme | −2.17 | 0.036 | Regulation of blood pressure, peptide catabolic process | |
| Serine dehydratase | −2.52 | 0.012 | Cellular amino acid metabolic process | |
| Solute carrier family 7 member 2 | −2.10 | 0.017 | Nitric oxide production involved in inflammatory response | |
| Serum amyloid A | −3.44 | 0.007 | Response to inflammatory stimuli | |
| Metallothionein 1A | −2.10 | 0.038 | Negative regulation of growth | |
| V-set and immunoglobulin domain containing 4 | −2.10 | 0.006 | Negative regulation of interleukin-2 production | |
| Rac/Cdc42 guanine nucleotide exchange factor 6 | −2.75 | 0.001 | Regulation of Rho protein signal transduction | |
| Adenosine A3 receptor | −2.14 | 0.009 | Neuroactive ligand-receptor interaction | |
| Polycystic kidney disease 1-like 3 | −2.45 | 0.018 | Transient Receptor Potential Interacting | |
| CD207 molecule, langerin | −5.60 | 0.034 | Defense response to virus | |
| Paired immunoglobulin-like type 2 receptor beta | −2.16 | 0.029 | Regulation of the immune system | |
| Src-like-adaptor 1 | −3.15 | 0.049 | Immune response | |
| Src-like-adaptor 3 | −2.00 | 0.020 | Immune response | |
| Src-like-adaptor 5 | −2.46 | 0.013 | Immune response | |
| Src-like-adaptor 7 | −3.27 | 0.012 | Antigen processing and presentation | |
| 3-hydroxy-3-methylglutaryl-CoA synthase 2 | −10.94 | 0.036 | Isoprenoid biosynthetic process | |
| Galanin like peptide | −14.31 | 0.012 | Neuropeptide signaling pathway | |
| Ubiquitin D | −3.53 | 0.048 | Ubiquitin-dependent protein catabolic process | |
| Major facilitator superfamily domain containing 2A | −2.80 | 0.009 | Establishment of blood-brain barrier | |
| Sphingomyelin phosphodiesterase 3 | −2.01 | 0.036 | Hematopoietic progenitor cell differentiation | |
| Cell growth regulator with EF-hand domain 1 | −2.47 | 0.027 | Calcium ion binding | |
| Chemokine (C-X-C motif) ligand 9 | −3.28 | 0.017 | Inflammatory response | |
| Histone H2B type 1 | −2.10 | 0.012 | Innate immune response in mucosa |
KEGG pathways associated with DEGs from the DON and ZEN dietary treatment groups
| KEGG ID | KEGG map name | Count | Gene names | p-value | Bonferroni | FDR |
|---|---|---|---|---|---|---|
| 01100 | Metabolic pathways | 9 | 4.44551E-07 | 0.00003.2896 | 3.28967E-05 | |
| 05332 | Graft-versus-host disease | 4 | 1.84987E-06 | 0.000136891 | 4.64776E-05 | |
| 05330 | Allograft rejection | 4 | 2.34925E-06 | 0.000173845 | 4.64776E-05 | |
| 04514 | Cell adhesion molecules (CAMs) | 5 | 2.51230E-06 | 0.000185910 | 4.64776E-05 | |
| 04940 | Type I diabetes mellitus | 4 | 3.14384E-06 | 0.000232644 | 4.65289E-05 | |
| 05320 | Autoimmune thyroid disease | 4 | 5.53981E-06 | 0.000409946 | 6.40058E-05 | |
| 05168 | Herpes simplex infection | 5 | 6.05460E-06 | 0.000448041 | 6.40058E-05 | |
| 05416 | Viral myocarditis | 4 | 1.02775E-05 | 0.000760534 | 9.50668E-05 | |
| 04612 | Antigen processing and presentation | 4 | 1.28527E-05 | 0.000951102 | 1.05678E-04 | |
| 04145 | Phagosome | 4 | 1.27643E-04 | 0.009445557 | 9.44556E-04 | |
| 05203 | Viral carcinogenesis | 4 | 2.59025E-04 | 0.019167814 | 1.59731E-03 | |
| 05169 | Epstein-Barr virus infection | 4 | 2.59025E-04 | 0.019167814 | 1.59731E-03 | |
| 05166 | HTLV-I infection | 4 | 5.93257E-05 | 0.043900983 | 2960192E-03 |
KEGG, Kyoto encyclopedia of genes and genomes; DEGs, differentially expressed genes; DON, deoxynivalenol; ZEN, zerolenone; FDR, false discovery rate; HTLV-I, human T-cell leukemia lymphoma virus I.
KEGG pathway IDs in DON and ZEN treatment groups.
Name of the KEGG pathway which is identified in DON and ZEN treatment groups.
Number of significant genes which is involved in KEGG pathways.
Name of the genes which are involved in the particular KEGG pathways.
Comparison of FCs estimated from RNA-Seq data from the DON and ZEN treatment groups and expression validation via quantitative real-time PCR
| Gene name | RNA-sequencing FC | qRT-PCR FC | ||||||
|---|---|---|---|---|---|---|---|---|
|
|
| |||||||
| DON/CON | p value | ZEN/CON | p value | DON/CON | p value | ZEN/CON | p value | |
| −3.90 | −2.43 | NS | −4.32 | −2.21 | NS | |||
| +2.24 | +1.62 | NS | 2.91 | 2.02 | ||||
| +3.59 | +1.01 | 3.83 | NS | 1. 32 | ||||
| +1.32 | NS | −2.38 | 1.16 | NS | −2.67 | |||
| +5.08 | −2.15 | 3.94 | −1.93 | |||||
| −1.46 | NS | −2.10 | −1.73 | NS | −2.79 | NS | ||
| −2.41 | −2.29 | −3.59 | −1.93 | |||||
| −2.16 | +1.04 | NS | −3.02 | NS | 0.67 | NS | ||
| −4.08 | −3.07 | −3.41 | −2.16 | |||||
| −1.30 | NS | −2.7 | −1.03 | NS | −2.08 | NS | ||
| +2.02 | +1.22 | NS | 1.92 | 1.19 | ||||
| +3.00 | +2.99 | 2.01 | 2.31 | |||||
FCs, fold changes; DON, deoxynivalenol; ZEN, zerolenone; PCR, polymerase chain reaction; qRT-PCR, quantitative real-time polymerase chain reaction.
IGF-I, insulin-like growth factor I; ORM1, orosomucoid 1; UBD, ubiquitin D; SLA-1, Src-like-adaptor-1; HMGCS2, hydroxy-3-methylglutaryl-CoA synthase 2; MT1A, metallothionein 1A; NOCT, nocturnin; TRHDE, thyrotropin-releasing hormone degrading enzyme; NNMT, nicotinamdie N-methyltransferase; ARHGEF6, rho guanine nucleotide exchange factor 6; CLDN4, claudin 4; PON3, paraoxonase 3; GAPDH, glyceraldehydes 3-phosphate.
Fold change values expressed as a ratio between DON and CON groups, and ZEN and CON groups, were FC>1.00 indicates an increase in gene expression and FC<–1 indicates a decrease in gene expression n = 5 for each of the CON (0 mg/kg of DON), DON (8 mg/kg of DON) and ZEN (0.8 mg/kg of ZEN) treatments.
p≤0.05;
NS, no significant.